Loading quotes...

Forecast

The analysts' average price target is €13.68 (+129.92%). The median is €13.68 (+129.92%).

Buy
  5
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • ImmunityBio stock rises after ANKTIVA approval in the UAE

    ImmunityBio shares climbed 7.5% after ANKTIVA was approved in the United Arab Emirates. The approval covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive, non‑muscle‑invasive bladder cancer and ANKTIVA 1.2 mg with immune checkpoint inhibitors for metastatic non‑small‑cell lung cancer. The approval expands ANKTIVA’s regulatory presence to 34 countries and is based on the QUILT‑3.032 study (in NMIBC: 71% complete response rate in the CIS cohort; 12‑month DFR 58.2% in papillary tumors; 83% cystectomy‑free at 36 months) and QUILT‑3.055 (in checkpoint‑refractory NSCLC: median overall survival 14.6 months). » More on de.investing.com


  • ImmunityBio analysis: ANKTIVA plus BCG significantly more cost-effective than TAR-200 in bladder cancer

    A health economic analysis presented in Philadelphia shows that ANKTIVA combined with BCG achieves substantial cost savings over three years compared with TAR-200 for BCG-unresponsive, non–muscle-invasive bladder cancer. Savings per avoided cystectomy were $109,622 in year 1, $151,438 in year 2 and $60,393 in year 3; savings per cystectomy-free month were $9,370, $6,144 and $1,520 in years 1–3, respectively. The study attributed the cost reductions to lower acquisition and administration costs and slightly higher complete response rates (49.6% vs. 45.9%). Investors reacted positively; the stock has returned 272% in the past six months and is trading at $7.74. » More on de.investing.com


  • ImmunityBio obtains exclusive US rights to Tokio-172 BCG

    ImmunityBio has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokio-172 BCG strain in the U.S. and could become the sole BLA applicant. The decision is based on Phase III SWOG S1602 data showing non-inferiority to TICE BCG (HR 0.82) and an estimated 5-year recurrence-free survival of 64% vs. 58%. Tokio-172 is not yet FDA-approved in the U.S.; ImmunityBio is in discussions with the FDA and research institutions about data use and plans regulatory steps. The company reports strong revenue growth but remains unprofitable, and analysts see further upside potential despite recent share gains. » More on de.investing.com


  • ImmunityBio posts strong Anktiva sales growth and expands global access

    ImmunityBio reported accelerating commercial traction for Anktiva with Q4 2025 net product revenue up 700% year‑over‑year and unit volumes rising 750%, driven by broadened physician and patient adoption. The company has expanded Anktiva access to 33 countries across four major regulatory jurisdictions and secured an FDA J‑code to improve reimbursement visibility. ImmunityBio is advancing a multi‑layered immunotherapy platform—Anktiva (IL‑15 superagonist), NaNT allogeneic cell therapy, DNA vaccines and Leonardo manufacturing for off‑the‑shelf NK/CAR‑NK products—that management says could scale into an API‑like personalized immune regimen and materially re‑rate the company if execution continues. Continued commercial momentum and regulatory tailwinds underpin a bullish long‑term thesis for IBRX, albeit with execution risk. » More on finance.yahoo.com


  • ImmunityBio posts 168% y/y product revenue jump as ANKTIVA launch gains traction

    ImmunityBio reported preliminary results for the quarter ending March 31, 2026, with product revenue rising 168% year over year to $44.2 million following the commercial launch of ANKTIVA. The company recorded $113 million net product revenue in 2025 (up 700% from 2024) and ended the quarter with $380.9 million in cash and cash equivalents. ANKTIVA has regulatory approval across five jurisdictions covering 34 countries, and ImmunityBio is focused on scaling U.S. commercialization and global expansion to broaden revenue streams. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, ImmunityBio has already paid €0.0574 in dividends. The last payout was in June.

Financials

In the last quarter, ImmunityBio had revenue of €43.12m and net profit of -€162.93m
(EUR) September 2026
YoY
Revenue 43.12m 57.83%
Gross profit 41.98m 76.37%
Net profit -162.93m 184.30%
EBITDA -131.24m 330.53%

Fundamentals

Metric Value
Market capitalization
€6.07bn
Number of shares
1.06bn
52-week high/low
€11.33 - €1.78
Dividend yield
1.05%
Dividends TTM
€0.0574
Beta
0.13
P/E ratio
-5.84
PEG ratio
0.05
P/B ratio
-5.79
P/S ratio
36.48

Company profile

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Name
ImmunityBio
CEO
Richard Gerald Adcock
Headquarters San Diego, ca
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
28/07/2015
Employees 688

Ticker symbols

Exchange Symbol
NASDAQ
IBRX
Frankfurt
26CA.F
DĂĽsseldorf
26CA.DU
MĂĽnchen
26CA.MU
🍪

Parqet  uses cookies. Learn more